Document:

Exhibit 10.2

 

FORM OF REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (the “Agreement”) is made and entered into as of this 2nd day of February, 2012, by and among Response
Genetics, Inc., a Delaware corporation (the “Company”), and the “Investor” named in that certain
Purchase Agreement, by and among the Company and the Investor, dated as of the date hereof (the “Purchase Agreement”).
Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined
herein.

 

The parties hereby agree
as follows:

 

1.     Certain
Definitions.

 

As used in this Agreement,
the following terms shall have the following meanings:

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries controls, is
controlled by, or is under common control with, such Person. The term “control” (including the terms “controlling,”
“controlled by” and “under common control with”) as used with respect to any Person means
the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“Business Day”
means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

 

“Common Stock”
means the Company’s common stock, par value $0.01 per share, and any securities into which such shares may hereinafter be
reclassified.

 

“Investor”
means the Investor identified in the Purchase Agreement and any Affiliate or permitted transferee of the Investor who is a subsequent
holder of any Registrable Securities.

 

“Nasdaq”
means The NASDAQ Capital Market.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Prospectus”
means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by
all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
or deemed to be incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in
Rule 405 under the 1933 Act (as defined below).

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act, and the declaration or ordering of effectiveness of such Registration
Statement or document.

 

“Registrable Securities”
means (i) the Shares and (ii) shares of capital stock or any other securities issued or issuable with respect to or in exchange
for the Shares; provided, that, a security shall cease to be a Registrable Security upon (A) sale pursuant to a Registration Statement
or Rule 144 under the 1933 Act, or (B) such security becoming eligible for sale without restriction by the Investor pursuant to
Rule 144(b)(1).

 

    	 

    	 

    

 

“Registration
Statement” means any registration statement of the Company filed under the 1933 Act that covers the resale of any of
the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement,
including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“Shares”
means the shares of Common Stock issued pursuant to the Purchase Agreement.

 

“Underwritten
Offering” means an offering in which shares of Common Stock are sold to an underwriter on a firm commitment basis for
reoffering to the public or an offering that is a “bought deal” with one or more investment banks.

 

“1933 Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

2.      Registration.

 

(a)          Registration
Statements. Promptly following the closing of the purchase and sale of the securities contemplated by the Purchase Agreement
(the “Closing Date”) but no later than ninety (90) days after the Closing Date (the “Filing Deadline”),
the Company shall prepare and file with the SEC one Registration Statement on Form S-3 (or, if Form S-3 is not then available to
the Company, on such form of registration statement as is then available to effect a registration for resale of the Registrable
Securities), covering the resale of the Registrable Securities. Subject to any SEC comments, such Registration Statement shall
include the plan of distribution attached hereto as Exhibit A; provided, however, that the Investor shall not be named as
an “underwriter” in the Registration Statement without the Investor’s prior written consent. Such Registration
Statement also shall cover, to the extent allowable under the 1933 Act and the rules promulgated thereunder (including Rule 416),
such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions
with respect to the Registrable Securities. Other than up to _________________ shares of Common Stock that are being sold by the
Company to certain other investors pursuant to purchase agreements entered into on or about the date hereof which may be included
in the Registration Statement, such Registration Statement shall not include any other shares of Common Stock or other securities
for the account of any other holder without the prior written consent of the Investor. The Registration Statement (and each amendment
or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section
3(c) to the Investor and its counsel prior to its filing or other submission.

    	- 2 -

    	 

    

 

(b)       Piggyback
Rights.

 

(i)         If
at any time during which there are Registrable Securities outstanding the Company proposes to register any of its common equity
securities under the 1933 Act (other than a registration statement on Form S-8 or on Form S-4 (or any similar successor forms thereto
or in connection with (A) an employee stock option, stock purchase or compensation plan or securities issued or issuable pursuant
to any such plan, or (B) a dividend reinvestment plan), whether for its own account or for the account of one or more shareholders
of the Company, and the registration form to be used may be used for any registration of Registrable Securities (a “Piggyback
Registration”), the Company shall give prompt written notice (in any event within twenty (20) days after its receipt
of notice of any exercise of other demand registration rights) to the Investor of its intention to effect such a registration and
shall include in such registration all such Registrable Shares with respect to which the Company has received written requests
for inclusion therein within fifteen (15) days after the receipt of the Company’s notice. The Company may postpone or withdraw
the filing or the effectiveness of a Piggyback Registration at any time in its sole discretion.

 

(ii)         If
a Piggyback Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise
the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the
number which can be sold in such offering without having an adverse effect on such offering, the Company shall include in such
registration (i) first, the securities the Company proposes to sell, (ii) second, the Registrable Securities requested to be included
therein by the Investor, and (iii) third, other securities requested to be included in such registration pro rata among the holders
of such securities on the basis of the number of shares requested to be registered by such holders or as such holders may otherwise
agree.

 

(iii)        If
a Piggyback Registration is an underwritten secondary registration on behalf of a holder of the Company’s securities other
than Registrable Securities, and the managing underwriters advise the Company in writing that in their opinion the number of securities
requested to be included in such registration exceeds the number which can be sold in such offering without having an adverse effect
on such offering, the Company shall include in such registration (i) first, the securities requested to be included therein by
the holders requesting such registration, (ii) second, the Registrable Securities requested to be included therein by the Investor,
and (iii) third, other securities requested to be included in such registration pro rata among the holders of such securities on
the basis of the number of shares requested to be registered by such holders or as such holders may otherwise agree.

 

(iv)        If
any Piggyback Registration is an underwritten primary offering, the Company shall have the right to select the managing underwriter
or underwriters to administer any such offering.

 

(c)         Expenses.
The Company will pay all expenses associated with each registration, including all registration, filing and securities exchange
listing fees, all word processing, duplicating and printing fees and expenses, the Company’s counsel and accounting fees
and expenses, costs associated with registration, filing, qualification and clearing the Registrable Securities for sale under
applicable state securities laws, Nasdaq listing fees, fees of the Financial Industry Regulatory Authority, transfer taxes and
fees of transfer agents and registrars, reasonable fees and expenses of the Investor’s counsel (not to exceed $25,000) and
the Investor’s reasonable expenses in connection with the registration, but excluding discounts, commissions, fees of underwriters,
selling brokers, dealer managers or similar securities industry professionals with respect to the Registrable Securities being
sold.

    	- 3 -

    	 

    

 

(d)        Effectiveness.

 

(i)          The
Company shall use commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable
after filing, and in any event no later than the earlier of (i) five (5) Business Days after the SEC shall have informed the Company
that no review of the Registration Statement will be made or that the SEC has no further comments on the Registration Statement
or (ii) the 180th day after the date hereof. The Company shall notify the Investor by facsimile or e-mail as promptly
as practicable, and in any event, within twenty-four (24) hours, after any Registration Statement is declared effective and shall
simultaneously provide the Investor with copies of any related Prospectus to be used in connection with the sale or other disposition
of the securities covered thereby.

 

(ii)         For
not more than twenty (20) consecutive days or for a total of not more than forty-five (45) days in any twelve (12)-month period,
the Company may suspend the use of any Prospectus included in any Registration Statement contemplated by this Section in the event
that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material non-public
information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the
best interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that
such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances
under which they were made, not misleading (an “Allowed Delay”); provided, that the Company shall promptly (a)
notify the Investor in writing of the commencement of and the reasons for an Allowed Delay, but shall not (without the prior written
consent of the Investor) disclose to the Investor any material non-public information giving rise to an Allowed Delay, (b) advise
the Investor in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use commercially
reasonable efforts to terminate an Allowed Delay as promptly as practicable. Upon disclosure of such information or the termination
of the condition giving rise to the Allowed Delay, the Company shall provide prompt notice to the Investor and shall promptly terminate
any suspension of sales it has put into effect and shall take such other actions to permit registered sales of Registrable Securities
as contemplated in this Agreement.

 

(e)          Rule
415; Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in
a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the
1933 Act or requires any Investor to be named as an “underwriter”, the Company shall use its commercially reasonable
best efforts to persuade the SEC that the offering contemplated by the Registration Statement is a valid secondary offering and
not an offering “by or on behalf of the issuer” as defined in Rule 415 and that the Investor is not an “underwriter”.
The Investor shall have the right to participate or have its counsel participate in any meetings or discussions with the SEC regarding
the SEC’s position and to comment or have its counsel comment on and approve any written submission made to the SEC with
respect thereto. No such written submission shall be made to the SEC to which the Investor’s counsel reasonably objects.
In the event that, despite the Company’s commercially reasonable best efforts and compliance with the terms of this Section
2(d), the SEC refuses to alter its position, the Company shall (i) remove from the Registration Statement such portion of
the Registrable Securities (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on
the registration and resale of the Registrable Securities as the SEC may require to assure the Company’s compliance with
the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that the Company shall
not agree to name the Investor as an “underwriter” in such Registration Statement without the prior written consent
of the Investor. From and after the date on which the SEC Restrictions terminate or expire, all of the provisions of this Section
2 shall again be applicable to the Cut Back Shares.

 

    	- 4 -

    	 

    

 

3.     Company
Obligations.  The Company will use reasonable best efforts to effect the registration of the Registrable Securities in accordance
with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible:

 

(a)          use
commercially reasonable efforts to cause such Registration Statement to become effective and to remain continuously effective for
a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration
Statement as amended from time to time, have been sold, (ii) the date on which there are no longer any Registrable Securities outstanding
or (iii) one year from the date hereof (the “Effectiveness Period”) and advise the Investor in writing when
the Effectiveness Period has expired;

 

(b)          prepare
and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be
necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933
Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;

 

(c)          provide
copies to and permit counsel designated by the Investor to review and comment on each Registration Statement and all amendments
and supplements thereto as far in advance as reasonably practicable but no fewer than seven (7) days prior to their filing with
the SEC and not file any document to which the Investor’s counsel reasonably objects;

 

(d)          furnish
to the Investor and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or
received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the case
may be) one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each
amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and
each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than
any portion of any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number
of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents
as the Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by the Investor
that are covered by the related Registration Statement;

    	- 5 -

    	 

    

 

(e)          use
commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if
such order is issued, obtain the withdrawal of any such order at the earliest possible moment;

 

(f)          prior
to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify or cooperate with
the Investor, underwriters and their counsel in connection with the registration or qualification of such Registrable Securities
for offer and sale under the securities or blue sky laws of such jurisdictions requested by the Investor and do any and all other
commercially reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable
Securities covered by the Registration Statement; provided, however, that the Company shall not be required in connection therewith
or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify
but for this Section 3(f), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject
but for this Section 3(f), or (iii) file a general consent to service of process in any such jurisdiction;

 

(g)          use
commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on Nasdaq
or each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are
then listed;

 

(h)          immediately
notify the Investor and each underwriter, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon
the happening of any event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state
any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing, and promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus
as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then
existing;

 

(i)          upon
request, furnish to the Investor copies of any and all transmittal letters or other correspondence with the SEC or any other governmental
agency or self-regulatory body or other body having jurisdiction (including any domestic or foreign securities exchange) relating
to such offering of Registrable Securities;

 

(j)          provide
a transfer agent and registrar for all Registrable Securities covered by such registration statement not later than the effective
date of such registration statement;

    	- 6 -

    	 

    

 

(k)          otherwise
use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934
Act, including, without limitation, Rule 172 under the 1933 Act (if applicable), file any final Prospectus, including any supplement
or amendment thereof, with the SEC pursuant to Rule 424 under the 1933 Act in order to ensure that it shall not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading, promptly inform the Investor in writing if,
at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result
thereof, the Investor is required to deliver a Prospectus in connection with any disposition of Registrable Securities and take
such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make
available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below),
an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration
Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the 1933 Act, including Rule 158 promulgated
thereunder (for the purpose of this subsection 3(i), “Availability Date” means the 45th day following the end
of the fourth fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth fiscal
quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the 90th day after the end
of such fourth fiscal quarter);

  

(l)          with
a view to making available to the Investor the benefits of Rule 144 (or its successor rule) and any other rule or regulation of
the SEC that may at any time permit the Investor to sell shares of Common Stock to the public without registration, covenant and
agree to: (i) make and keep public information available, as those terms are understood and defined in Rule 144, until the earlier
of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the holders thereof pursuant
to Rule 144 without regard to any volume limitation or current information requirements thereunder or (B) such date as all of the
Registrable Securities shall have been resold; (ii) file with the SEC in a timely manner all reports and other documents required
of the Company under the 1934 Act; and (iii) furnish to the Investor upon request, as long as the Investor owns any Registrable
Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the 1934 Act, (B) a
copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information
as may be reasonably requested in order to avail the Investor of any rule or regulation of the SEC that permits the selling of
any such Registrable Securities without registration; and

 

(m)          take
such other actions as are reasonably requested by the Investor in order to expedite or facilitate the disposition of such Registrable
Securities.

 

4.          Due
Diligence Review; Information. The Company shall make available, during normal business hours, for inspection and review by
the Investor, underwriters, advisors to and representatives of the Investor (who may or may not be affiliated with the Investor
and who are reasonably acceptable to the Company), all financial and other records, and all other corporate documents and properties
of the Company as may be reasonably necessary for the purpose of such review, and cause the Company’s officers, directors
and employees, within a reasonable time period, to supply all such information reasonably requested by the Investor or any such
representative, advisor or underwriter in connection with such Registration Statement (including, without limitation, in response
to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing
and effectiveness of the Registration Statement for the sole purpose of enabling the Investor and such representatives, advisors
and underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to the
Company and the accuracy of such Registration Statement.

    	- 7 -

    	 

    

 

The Company shall not
disclose material nonpublic information to the Investor, or to advisors to or representatives of the Investor, unless prior to
disclosure of such information the Company identifies such information as being material nonpublic information and provides the
Investor, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information
for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the Company
with respect thereto.

 

5.    Obligations
of the Investor.

 

(a)          The
Investor shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the
intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration
of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably
request. At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement, the Company
shall notify the Investor of the information the Company requires from the Investor if the Investor elects to have any of the Registrable
Securities held by it included in the Registration Statement. The Investor shall provide such information to the Company at least
two (2) Business Days prior to the first anticipated filing date of such Registration Statement if the Investor elects to have
any of such Registrable Securities included in the Registration Statement.

 

(b)          The
Investor, by its acceptance of the Registrable Securities agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of a Registration Statement hereunder, unless the Investor has notified the Company
in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

(c)          The
Investor agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to
Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, the Investor will immediately
discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities,
until the Investor is advised by the Company in writing that such dispositions may again be made.

    	- 8 -

    	 

    

 

6.          Indemnification.

 

(a)          Indemnification
by the Company. The Company shall indemnify and hold harmless the Investor and its officers, directors, members, employees
and agents, successors and assigns, and each other person, if any, who controls the Investor within the meaning of the 1933 Act,
against any losses, claims, damages, expenses or liabilities (including reasonable attorneys’ fees and expenses) (collectively,
“Losses”), joint or several, to which they may become subject under the 1933 Act, the 1934 Act or otherwise,
insofar as such Losses (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based
upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any
Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof, or any free writing
prospectus related thereto; (ii) any blue sky application or other document executed by the Company specifically for that purpose
or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or
all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called
a “Blue Sky Application”); (iii) the omission or alleged omission to state in a Blue Sky Application a material fact
required to be stated therein or necessary to make the statements therein not misleading; (iv) any violation by the Company or
its agents of any rule or regulation promulgated under the 1933 Act or the 1934 Act applicable to the Company or its agents and
relating to action or inaction required of the Company in connection with such registration; or (v) any failure to register or
qualify the Registrable Securities included in any such Registration Statement in any state where the Company or its agents has
affirmatively undertaken or agreed in writing that the Company will undertake such registration or qualification on the Investor’s
behalf and will reimburse the Investor, and each such officer, director or member and each such controlling person for any legal
or other expenses reasonably incurred by them in connection with investigating or defending any such Loss, action or proceeding;
provided, however, that the Company will not be liable in any such case if and to the extent that any such Loss arises out of or
is based upon (1) an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information
furnished by the Investor or any such controlling person in writing specifically for use in such Registration Statement or Prospectus
or (2) the delivery by the Investor of an outdated or defective Prospectus after the Company has notified the Investor in writing
that the Company does not meet the conditions for use of Rule 172 and that (A) as a result the Investor must deliver a Prospectus
in connection with any sales under the Registration Statement and (B) the Prospectus is outdated or defective and prior to the
receipt by the Investor of an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the
amended or supplemented Prospectus the misstatement or omission giving rise to such loss, claim, damage or liability would have
been corrected.

 

(b)          Indemnification
by the Investor. The Investor shall indemnify and hold harmless, to the fullest extent permitted by applicable law, the Company,
its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of the 1933 Act)
against any Losses (including reasonable attorney fees) resulting from (x) the Investor’s failure to deliver a Prospectus
in connection with any sales under the Registration Statement after the Company has advised the Investor in writing that (A) the
Company does not meet the conditions for use of Rule 172 and (B) as a result the Investor must deliver a Prospectus in connection
with any sales under the Registration Statement or (y) any untrue statement of a material fact or any omission of a material fact
required to be stated in the Registration Statement or Prospectus or preliminary Prospectus or amendment or supplement thereto
or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or
omission is contained in (1) any information furnished in writing by the Investor to the Company specifically for inclusion in
such Registration Statement or Prospectus or amendment or supplement thereto or (2) in an outdated or defective Prospectus delivered
by the Investor in connection with any sales under the Registration Statement after the Company has notified the Investor in writing
that the Company does not meet the conditions for use of Rule 172 and that (A) as a result the Investor must deliver a Prospectus
in connection with any sales under the Registration Statement and (B) the Prospectus is outdated or defective and prior to the
receipt by the Investor of an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the
amended or supplemented Prospectus the misstatement or omission giving rise to such loss, claim, damage or liability would have
been corrected. In no event shall the liability of the Investor be greater in amount than the dollar amount of the proceeds (net
of all expense paid by the Investor in connection with any claim relating to this Section 6 and the amount of any damages
the Investor has otherwise been required to pay by reason of such untrue statement or omission) received by the Investor upon the
sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.

    	- 9 -

    	 

    

 

(c)          Conduct
of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification
hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses
of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses,
or (b) the indemnifying party shall have failed to assume the defense of such claim within a reasonable period of time and employ
counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice
of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which
case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense
of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such
person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the
indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely
affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall
not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm
of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified
party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.
No indemnifying party shall be liable for any settlement of any proceeding effected without its written consent, which consent
shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff, the indemnifying
party shall indemnify and hold harmless such indemnified party from and against any loss or liability by reason of such settlement
or judgment.

    	- 10 -

    	 

    

 

(d)          Contribution.
If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party
or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to
the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as
is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant
equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act
shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall the contribution
obligation of a holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses
paid by such holder in connection with any claim relating to this Section 6 and the amount of any damages such holder has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon
the sale of the Registrable Securities giving rise to such contribution obligation.

 

(e)          The
indemnification provided for under this Section 6 shall remain in full force and effect regardless of any investigation made by
or on behalf of the indemnified party and shall survive the transfer of securities.

 

(f)          The
provisions of this Section 6 shall be in addition to any other rights to indemnification or contribution which an indemnified
party may have pursuant to law, equity, contract or otherwise.

 

7.          Miscellaneous.

 

(a)          Amendments
and Waivers. This Agreement may be amended only by a writing signed by the Company and the Investor; provided, however, that
no such amendment which adversely affects the Investor shall be binding on the Investor without its written consent. The Company
may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall
have obtained the written consent to such amendment, action or omission to act, of the Investor; provided, however, that no such
amendment, action or omission which disproportionately and materially adversely affects the Investor shall be binding on the Investor
without its written consent.

 

(b)          Notices.
All notices and other communications provided for or permitted hereunder shall be made as set forth in Section 9.4 of the
Purchase Agreement.

 

(c)          Assignments
and Transfers by the Investor. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor
and its respective successors and assigns. The Investor may transfer or assign, in whole or from time to time in part, to one or
more persons its rights hereunder in connection with the transfer of Registrable Securities by the Investor to such person, provided
that the Investor complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after
such assignment is effected.

 

(d)          Assignments
and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise)
without the prior written consent of the Investor, provided, however, that the Company may assign its rights and delegate its duties
hereunder to any surviving or successor corporation in connection with a merger or consolidation of the Company with another corporation,
or a sale, transfer or other disposition of all or substantially all of the Company’s assets to another corporation, without
the prior written consent of the Investor, after notice duly given by the Company to the Investor.

    	- 11 -

    	 

    

 

(e)          Benefits
of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(f)          Counterparts;
Faxes. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also be executed and transmitted via facsimile, or by
portable document format via electronic mail, which shall be deemed an original.

 

(g)         Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

(h)          Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable
in any respect.

 

(i)          Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

(j)          Entire
Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete
and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein.
This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter.

    	- 12 -

    	 

    

 

(k)         Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with,
the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or
proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices
under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action
or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue
of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding
brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST
A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS
TO THIS WAIVER.

  

(l)          Specific
Performance. Damages in the event of breach of this Agreement by a party hereto may be difficult, if not impossible, to ascertain,
and it is therefore agreed that each such Person, in addition to and without limiting any other remedy or right it may have, will
have the right to an injunction or other equitable relief in any court of competent jurisdiction, enjoining any such breach, and
enforcing specifically the terms and provisions hereof, and each of the parties hereto hereby waives any and all defenses it may
have on the ground of lack of jurisdiction or competence of the court to grant such an injunction or other equitable relief. The
existence of this right will not preclude any such Person from pursuing any other rights and remedies at law or in equity which
such Person may have.

 

[Signature Pages Follow]

  

    	- 13 -

    	 

    

  

IN WITNESS WHEREOF, the
parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above
written.

 

	The Company:	RESPONSE GENETICS, INC.
	 	 
	 	By:	 	 
	 	Name:
	 	Title:

 

[Signature Page – Registration Rights
Agreement]

   

    	 

    	 

    

  

IN WITNESS WHEREOF, the parties
have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

 

	The Investor:	[NAME OF INVESTOR]
	 	 
	 	By: 	 	 
	 	Name: 
	 	Title: 

 

[Signature Page – Registration Rights
Agreement]

   

    	 

    	 

    

   

Exhibit A

 

Plan of Distribution

 

    	 

    	 

    

  

Exhibit A

 

Plan of Distribution

 

The selling stockholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests
in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership
distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common
stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling stockholders
may use any one or more of the following methods when disposing of shares or interests therein:

 

- ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;

 

- one or more block trades
in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal
to facilitate the transaction;

 

- purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;

 

- an exchange distribution
in accordance with the rules of the applicable exchange;

 

- public or privately negotiated
transactions;

 

- on The NASDAQ Capital
Market (or through the facilities of any national securities exchange or U.S. inter-dealer quotation system of a registered national
securities association, on which the shares are then listed, admitted to unlisted trading privileges or included for quotation);

 

- through underwriters,
brokers or dealers (who may act as agents or principals) or directly to one or more purchasers;

 

- to cover short sales
effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

 

- through the writing or
settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

- broker-dealers may agree
with the selling stockholders to sell a specified number of such shares at a stipulated price per share; and

 

    	 

    	 

    

  

- a combination of any
such methods of sale; and

 

any
other method permitted pursuant to applicable law.

 

In connection with distributions of the shares
or otherwise, the selling stockholders may:

  

	·	enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares in the course of hedging the positions they assume;
	·	sell the shares short and redeliver the shares to close out such short positions;
	·	enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to them of shares offered by this prospectus, which they may in turn resell; and
	·	pledge shares to a broker-dealer or other financial institution, which, upon a default, they may in turn resell.

 

The selling stockholders
may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of
common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.

 

In connection with the
sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The aggregate proceeds
to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less
discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.
We will not receive any of the proceeds from this offering.

 

The selling stockholders
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of
1933, provided that they meet the criteria and conform to the requirements of that rule.

  

    	 

    	 

    

  

The selling stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be "underwriters"
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are "underwriters"
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.

 

To the extent required,
the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.

 

In order to comply with
the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.

 

We have advised the selling
stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market
and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies
of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose
of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the Securities Act.

 

We have agreed to indemnify
the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating
to the registration of the shares offered by this prospectus.

 

We have agreed with the
selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier
of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration
statement or (2) the date on which the shares may be sold without restriction pursuant to Rule 144 of the Securities Act without
regard to any volume limitation requirements thereunder.EXHIBIT 10.1

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement
(this “Agreement”), dated February 3, 2012, by and between Adeona Pharmaceuticals, Inc., a corporation organized under
the laws of the State of Nevada (the “Corporation”), and Jeffrey Riley, an individual (the “Executive”).

 

1.           EMPLOYMENT;
DUTIES

 

(a)The Corporation
hereby engages and employs Executive as the Chairman of the Board of Directors, Chief Executive Officer and President of the Corporation,
and Executive hereby accepts such engagement and employment as Chairman of the Board of Directors, Chief Executive Officer and
President of the Corporation, for the term of this Agreement as long as Executive desires to serve. It is expected that Executive
will perform such duties commensurate with such titles and as the Board of Directors of the Corporation shall reasonably determine,
and the employment duties of Executive will include reporting directly to the Board of Directors of the Corporation for the full
time high quality performance of directing, supervising and having responsibility for all aspects of the operations and general
affairs of the Corporation as directed by the Board of Directors. Executive further agrees to serve without additional compensation
as an officer or director of any subsidiaries of the Corporation upon request of the Board of Directors.

 

(b)Executive
shall devote substantially all of his professional time under this Agreement to the business of the Corporation. Executive’s
employment under this Agreement shall be Executive’s exclusive employment during the term of this Agreement.  Executive
may not engage, directly or indirectly, in any other business, investment, or activity that interferes with Executive's performance
of Executive's duties hereunder, is contrary to the interest of the Corporation or any of its subsidiaries, or requires any significant
portion of Executive's business time.  The foregoing notwithstanding, the parties recognize and agree that Executive
may engage in personal investments, other business activities and civic, charitable or religious activities which do not conflict
with the business and affairs of the Corporation or interfere with Executive's performance of his duties hereunder.  Executive
may not serve on the board of directors of any entity other than the Corporation during the Term (as hereinafter defined) without
the written approval of the Board of Directors.  Executive shall be permitted to retain any compensation received for
approved service on any unaffiliated corporation's board of directors.

(c)The Corporation
shall pay or reimburse reasonable travel, lodging, meal and related incidental costs of the Executive when the Executive is requested
to travel to or from the Corporation’s locations and while on business for the Corporation, consistent with the Corporation’s
travel policies in effect from time to time.

(d)The Corporation
shall provide a computer, cellular phone and office for Executive.

 

2.           TERM

 

The term (the “Term”) of Executive’s
employment shall be three (3) years from the execution date of this Agreement unless terminated earlier under Section 9 of this
Agreement. The parties may extend the Term for an additional three (3) year period upon mutual consent of Executive and the Board
of Directors of the Corporation, upon terms to be agreed upon by the parties.

 

    	-1-

    	 

    
 

 

3.           COMPENSATION

 

(a)As compensation
for the performance of his duties on behalf of the Corporation, Executive shall receive the following:

 

(i)           
Base Salary. Executive shall receive an annual base salary of Three Hundred Forty Eight Thousand Dollars ($348,000) for
the Term (the “Base Salary”), payable semi-monthly.

 

(ii)           
Bonus. The Executive shall be eligible for an annual bonus of up to fifty percent (50%) of his base salary payable in cash
or equity. Any bonus that may be awarded will be in the sole and absolute discretion of both the Compensation Committee and the
Board of Directors of the Corporation. The amount of such bonus shall depend on the achievement by the Executive and/or the Corporation
of certain objectives to be established by the Board or the Compensation Committee in consultation with the Executive, along with
such other factors the Board and Compensation Committee deems relevant. Any bonus for a given fiscal year shall be payable in one
lump sum upon approval by the Board of Directors of the Corporation or the Compensation Committee, which shall be obtained by the
Corporation on or about January 31 of the following year.

   

(b)The Corporation
shall reimburse Executive for all normal, usual and necessary expenses incurred by Executive, including all travel, lodging and
entertainment, against receipt by the Corporation, as the case may be, of appropriate vouchers or other proof of Executive’s
expenditures and otherwise in accordance with such Expense Reimbursement Policy as may from time to time be adopted by the Corporation.

 

(c)The Executive shall receive a non-restricted
option to purchase 750,000 shares of the Corporation’s publicly traded common stock. The option shall be exercisable at the
market price per share on the date hereof. The option will vest monthly on each monthly anniversary of the date hereof and for
thirty six (36) successive months while Executive is employed by the Corporation and such options will remain exercisable for a
period of ten (10) years from the date of grant, unless terminated earlier. Other terms of the option, including the period to
exercise such options following termination of employment, shall be according to the Corporation’s existing stock option
plan.

 

(d)The Corporation
shall provide Executive with full advance indemnification to the extent permitted by Nevada law, including indemnification for
activities at all subsidiaries.

 

(e)Executive shall
be entitled to four (4) weeks paid vacation and sick leave in accordance with the Corporation’s policies. The Corporation
shall provide Executive and his family with healthcare coverage pursuant to the Corporation’s healthcare insurance policy
plan as well as any other benefits provided to executive officers.

 

4.           REPRESENTATIONS
AND WARRANTIES BY EXECUTIVE

 

Executive hereby represents and warrants to
the Corporation as follows:

 

(a)           Neither
the execution and delivery of this Agreement nor the performance by Executive of his duties and other obligations hereunder violates
or will violate any statute, law, determination or award, or conflict with or constitute a default under (whether immediately,
upon the giving of notice or lapse of time or both) any prior employment agreement, contract, or other instrument to which Executive
is a party or by which he is bound.

 

    	-2-

    	 

    
 

 

(b)           Executive
has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and other obligations
hereunder. This Agreement constitutes the legal, valid and binding obligation of Executive enforceable against him in accordance
with its terms. No approvals or consents of any persons or entities are required for Executive to execute and deliver this Agreement
or perform his duties and other obligations hereunder.

 

6.           CONFIDENTIAL
INFORMATION

 

(a)           Executive
agrees that during the course of his employment or at any time thereafter, he will not disclose or make accessible to any other
person, the Corporation’s products, services and technology, both current and under development, promotion and marketing
programs, lists, trade secrets and other confidential and proprietary business information of the Corporation or any affiliates
or any of their clients. Executive agrees: (i) not to use any such information for himself or others, and (ii) not to take any
such material or reproductions thereof from the Corporation’s facilities at any time during his employment by the Corporation
other than to perform his duties hereunder. Executive agrees immediately to return all such material and reproductions thereof
in his possession to the Corporation upon request and in any event upon termination of employment.

 

(b)           Except
with prior written authorization by the Corporation, Executive agrees not to disclose or publish any of the confidential, technical
or business information or material of the Corporation, its clients or any other party to whom the Corporation owes an obligation
of confidence, at any time during or after his employment with the Corporation.

 

(c)           In
the event that Executive breaches any provisions of this Section 6 or there is a threatened breach, then, in addition to any other
rights which the Corporation may have, the Corporation shall be entitled, without the posting of a bond or other security, to injunctive
relief to enforce the restrictions contained herein. In the event that an actual proceeding is brought in equity to enforce the
provisions of this Section 6, Executive shall not urge as a defense that there is an adequate remedy at law, nor shall the Corporation
be prevented from seeking any other remedies which may be available. In addition, Executive agrees that in the event that he breaches
the covenants in this Section 6, in addition to any other rights that the Corporation may have, Executive shall be required to
pay to the Corporation any amounts he receives in connection with such breach.

 

(d)           Executive
recognizes that in the course of his duties hereunder, he may receive from the Corporation or others information which may be considered
“material, non-public information” concerning a public company that is subject to the reporting requirements of the
United States Securities and Exchange Act of 1934, as amended. Executive agrees not to:

 

(i)           Buy
or sell any security, option, bond or warrant while in possession of relevant material, non-public information received from the
Corporation or others in connection herewith, and

 

(ii)           Provide
the Corporation with information with respect to any public company that may be considered material, non-public information, unless
first specifically agreed to in writing by the Corporation.

 

    	-3-

    	 

    
 

 

 7.           INVENTIONS DISCOVERED BY EXECUTIVE

 

Executive shall promptly disclose to the Corporation
any invention, improvement, discovery, process, formula, or method or other intellectual property, whether or not patentable or
copyrightable (collectively, "Inventions"), conceived or first reduced to practice by Executive, either alone or jointly
with others, while performing services hereunder (or, if based on any Confidential Information, within one (1) year after the Term),
(a) which pertain to any line of business activity of the Corporation, whether then conducted or then being actively planned by
the Corporation, with which Executive was or is involved, (b) which is developed using time, material or facilities of the Corporation,
whether or not during working hours or on the Corporation premises, or (c) which directly relates to any of Executive’s work
during the Term, whether or not during normal working hours. Executive hereby assigns to the Corporation all of Executive’s
right, title and interest in and to any such Inventions. During and after the Term, Executive shall execute any documents necessary
to perfect the assignment of such Inventions to the Corporation and to enable the Corporation to apply for, obtain and enforce
patents, trademarks and copyrights in any and all countries on such Inventions, including, without limitation, the execution of
any instruments and the giving of evidence and testimony, without further compensation beyond Executive’s agreed compensation
during the course of Executive’s employment. All such acts shall be done without cost or expense to Executive. Executive
shall be compensated for the giving of evidence or testimony after the term of Executive’s employment at the rate of $1,000/day.
Without limiting the foregoing, Executive further acknowledges that all original works of authorship by Executive, whether created
alone or jointly with others, related to Executive’s employment with the Corporation and which are protectable by copyright,
are "works made for hire" within the meaning of the United States Copyright Act, 17 U.S .C. (S) 101, as amended, and
the copyright of which shall be owned solely, completely and exclusively by the Corporation. If any Invention is considered to
be work not included in the categories of work covered by the United States Copyright Act, 17 U. S. C. (S) 101, as amended, such
work is hereby assigned or transferred completely and exclusively to the Corporation. Executive hereby irrevocably designates counsel
to the Corporation as Executive's agent and attorney-in-fact to do all lawful acts necessary to apply for and obtain patents and
copyrights and to enforce the Corporation's rights under this Section. This Section 7 shall survive the termination of this Agreement.
Any assignment of copyright hereunder includes all rights of paternity, integrity, disclosure and withdrawal and any other rights
that may be known as or referred to as "moral rights" (collectively "Moral Rights"). To the extent such Moral
Rights cannot be assigned under applicable law and to the extent the following is allowed by the laws in the various countries
where Moral Rights exist, Executive hereby waives such Moral Rights and consents to any action of the Corporation that would violate
such Moral Rights in the absence of such consent. Executive agrees to confirm any such waivers and consents from time to time as
requested by the Corporation.

 

8.NON-COMPETE; NON-SOLICITATION

 

(a)NON-COMPETE.  For
a period commencing on the date hereof and ending one (1) year after the date Executive ceases to be employed by the Corporation
(the "Non-Competition Period"), Executive shall not, directly or indirectly, either for himself or any other person,
own, manage, control, materially participate in, invest in, permit his name to be used by, act as consultant or advisor to, render
material services for (alone or in association with any person, firm, corporation or other business organization) or otherwise
assist in any manner any business which develops, markets or sells products in the field of gene therapy or that are directly competitive
with the products being developed or sold by the Corporation at the time of termination (collectively, a "Competitor").  Nothing
herein shall prohibit Executive from being a passive owner of not more than five percent (5%) of the equity securities of a Competitor
which is publicly traded, so long as he has no active participation in the business of such Competitor.

 

    	-4-

    	 

    
 

 

(b)NON-SOLICITATION.  During
the Non-Competition Period, Executive shall not, directly or indirectly, (i) induce or attempt to induce or aid others in inducing
anyone working at or for the Corporation to cease working at or for the Corporation, or in any way interfere with the relationship
between the Corporation and anyone working at or for the Corporation except in the proper exercise of Executive’s authority
or (ii) in any way interfere with the relationship between the Corporation and any customer, supplier, licensee or other business
relation of the Corporation.

 

(c)SCOPE.  If,
at the time of enforcement of this Section 8, a court shall hold that the duration, scope, area or other restrictions stated herein
are unreasonable under circumstances then existing, the parties agree that the maximum duration, scope, area or other restrictions
reasonable under such circumstances shall be substituted for the stated duration, scope, area or other restrictions.

 

(d)INDEPENDENT
AGREEMENT.  The covenants made in this Section 8 shall be construed as an agreement independent of any other provisions
of this Agreement, and shall survive the termination of this Agreement.  Moreover, the existence of any claim or cause
of action of Executive against the Corporation or any of its affiliates, whether or not predicated upon the terms of this Agreement,
shall not constitute a defense to the enforcement of these covenants.

 

(e)EXCEPTIONS. The
Non-Competition Period shall be reduced to a period ending on the six month anniversary of the date of termination of this Agreement
if such termination is by the Corporation without Just Cause (as defined in Section 9 below) or by the Executive for Good Reason
(as defined in Section 9 below).

 

9.           TERMINATION

 

Executive’s employment hereunder shall
continue as set forth in Section 2 hereof unless terminated upon the first to occur of the following events:

 

(a)The Executive’s death.

 

(b)The Executive’s “Disability”,
meaning the Executive’s incapacity, due to physical or mental illness, which results in Executive having been absent from
fully performing his duties with the Company for a continuous period of more than sixty (60) days or more than ninety (90) days
in any period of three hundred sixty-five (365) consecutive days. In the event that
the Corporation intends to terminate the employment of Executive by reason of Disability, the Corporation shall give the Executive
no less than thirty (30) days’ prior written notice of the Corporation’s intention to terminate Executive’s employment.  The
Executive agrees, in the event of any dispute hereunder as to whether a Disability exists, and if requested by the Corporation,
to submit to a physical examination in the state of the Corporation’s executive offices by a licensed physician selected
by mutual agreement between the Corporation and the Executive, the cost of such examination to be paid by the Corporation. The
written medical opinion of such physician shall be conclusive and binding upon each of the parties hereto as to whether a Disability
exists and the date when such Disability arose. If the Executive refuses to submit to appropriate examinations by such physician
at the request of the Corporation, the determination of the Executive’s Disability by the Corporation in good faith will
be conclusive as to whether such Disability exists. This Agreement shall be interpreted and applied so as to comply with
the provisions of the Americans with Disabilities Act (to the extent that it is applicable) and any other applicable laws regarding
disability.

 

    	-5-

    	 

    
 

 

(c)          “Just
Cause”, meaning the Executive’s:

 

(i)gross insubordination;
acts of embezzlement or misappropriation of funds; fraud; dereliction of fiduciary obligations;

 

(ii)conviction
of a felony or other crime involving moral turpitude, dishonesty or theft;

 

(iii)willful unauthorized
disclosure of confidential information belonging to the Corporation or entrusted to the Corporation by a client;

 

(iv) material
violation of any provision of the Agreement, which is not cured by Executive within thirty (30) days of receiving written notice
of such violation by the Corporation;

 

(v) being under
the influence of drugs (other than prescription medicine or other medically-related drugs to the extent that they are taken in
accordance with their directions) during the performance of Executive’s duties under this Agreement;

 

(vi) engaging
in behavior that would constitute grounds for liability for harassment (as proscribed by the U.S. Equal Employment Opportunity
Commission Guidelines or any other applicable state or local regulatory body) or other egregious conduct that violates laws governing
the workplace;

 

(vii) willful
failure to perform his written assigned tasks, where such failure is attributable to the fault of Executive which is not cured
by Executive within thirty (30) days of receiving written notice of such violation by the Corporation..

 

In the event that the Corporation
intends to terminate the employment of Executive by reason of Just Cause, the Corporation shall give the Executive written notice
of the Corporation’s intention to terminate Executive’s employment, and such termination may be effective immediately,
unless a cure period applies, in which case the termination date may not precede the expiration date of the applicable cure period.

 

(d)         “Without
Just Cause”, meaning written notice by the Corporation to the Executive of a termination without Just Cause and other than
due to death or Disability.

 

(e)“Good Reason”, meaning:

 

(i)                 
a material breach by the Corporation of the terms of this Agreement, which breach is not cured within thirty (30) days after
notice thereof from Executive; or

 

(ii)               
an assignment to Executive of any duties materially inconsistent with Executive’s position(including status, office,
title and reporting requirements) authority, duties or responsibilities as contemplated by this Agreement which results in material
diminution in such position, authority, duties or responsibilities, specifically excluding for this purpose an isolated and insubstantial
action not taken in bad faith which is remedies by the Corporation after receipt of notice thereof given by Executive; or

 

    	-6-

    	 

    
 

 

(iii)   a change
in control which shall mean (a) any person becomes the beneficial owner (as term is defined in the Securities Exchange Act of 1934)
directly or indirectly, of securities representing more than fifty percent (50%) of the total voting power of Company’s shares;
or (b) a change in the composition of the Board of Directors as a result of which fewer than a majority of the directors are Incumbent
Directors.  Incumbent Directors shall mean directors who are either directors of the Company on the date hereof or are
elected by the Board of Directors with the affirmative vote of a majority of the Incumbent Directors at the time of election; or
(c) the Company merges with another corporation after which a majority of the shares of the resulting entity are not held by shareholders
of the Company prior to the merger.

In the event that the Executive
intends to terminate his employment for Good Reason, the Executive shall give the Corporation written notice of his intention to
terminate his employment, and such termination may be effective immediately, unless a cure period applies, in which case the termination
date may not precede the expiration date of the applicable cure period.

 

(f)           Without
Good Reason, meaning written notice by the Executive to the Corporation of a termination without Good Reason.

 

If the Executive’s
employment hereunder is terminated for any reason, the Executive or his estate as the case may be, will be entitled to receive
the accrued base salary, vacation pay, expense reimbursement and any other entitlements accrued by Executive under Section 2(b),
to the extent not previously paid (the sum of the amounts described in this subsection shall be hereinafter referred to as the
“Accrued Obligations”); provided, however, that if Executive’s employment is terminated (1) by
the Corporation without Just Cause or by the Executive for Good Reason then in addition to paying the Accrued Obligations , the
Corporation shall continue to pay the Executive his then- current base salary and continue to provide benefits to the Executive
at least equal to those which he had at the time of termination for a period of six months after termination and (y) Executive
shall have the right to exercise any vested options until the earlier of the expiration of the severance or the expiration of the
term of the option, or (2) by reason of death or Disability, then in addition to paying the Accrued Obligations, Executive shall
have the right to exercise any vested options until the expiration of the term of the option. If Executive commences employment
with another employer and is eligible to receive medical or other welfare benefits under another employer-provider plan, the medical
and other welfare benefits to be provided by the Corporation as described herein shall terminate.

 

10.           NOTICES

 

Any notice or other communication under this
Agreement shall be in person or in writing and shall be deemed to have been given (i) when delivered personally against receipt
therefor, (ii) one (1) day after being sent by Federal Express or similar overnight delivery, (iii) three (3) days after being
mailed registered or certified mail, postage prepaid, return receipt requested, to either party at the address set forth above,
or to such other address as such party shall give by notice hereunder to the other party, or (iv) when sent by facsimile, followed
by oral confirmation and with a hard copy sent as in (ii) or (iii) above.

 

11.           SEVERABILITY
OF PROVISIONS

 

If any provision of this Agreement shall be
declared by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part, such provision
shall be interpreted so a to remain enforceable to the maximum extent permissible consistent with applicable law and the remaining
conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable to the extent
they are valid, legal and enforceable, and no provision shall be deemed dependent upon any other covenant or provision unless so
expressed herein.

 

    	-7-

    	 

    
 

 

12.           ENTIRE
AGREEMENT MODIFICATION

 

This Agreement contains the entire agreement
of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties
relating to the subject matter of this Agreement which are not set forth herein. No modification of this Agreement shall be valid
unless made in writing and signed by the parties hereto.

 

13.           BINDING
EFFECT

 

The rights, benefits, duties and obligations
under this Agreement shall inure to, and be binding upon, the Corporation, its successors and assigns, and upon Executive and his
legal representatives. This Agreement constitutes a personal service agreement, and the performance of Executive’s obligations
hereunder may not be transferred or assigned by Executive.

 

14.           NON-WAIVER

 

The failure of either party to insist upon
the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment
of future compliance therewith, and said terms, conditions and provisions shall remain in full force and effect. No waiver of any
term or condition of this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver
is in writing and signed by such party.

 

15           GOVERNING
LAW, DISPUTE RESOLUTION

 

This Agreement shall be governed by, and construed
and interpreted in accordance with, the laws of the State of Virginia of the United States of America without regard to principles
of conflict of laws. The State of Virginia shall be the exclusive jurisdiction for any disputes arising under this Agreement and
the Parties hereby consent to such jurisdiction.

 

16.           HEADINGS

 

The headings of paragraphs are inserted for
convenience and shall not affect any interpretation of this Agreement.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the day and year first above written.

 

Corporation:

 

ADEONA PHARMACEUTICALS, INC.

 

By:  /s/ Lara M.
Guzman                

Title:  Authorized
agent 

 

Executive:

 

/s/ Jeffrey Riley                              

Jeffrey
Riley 

 

 

    	-8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]